Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada

(1) Background: Bispecific antibodies (BsAbs) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) can be delivered in ambulatory healthcare settings; however, the safe and effective management of potential side effects, such as cytokine release syndrome (CRS), requires...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: David MacDonald, Robert Puckrin, Pamela Skrabek, Selay Lam, Jai Jayakar, Isabelle Fleury, Christopher Lemieux, Mélina Boutin, Jacqueline Costello
Format: Article
Language:English
Published: MDPI AG 2025-08-01
Subjects:
diffuse large B-cell lymphoma
bispecific antibodies
T-cell engaging therapy
relapsed refractory lymphoma
epcoritamab
glofitamab
Online Access:https://www.mdpi.com/1718-7729/32/8/460

Internet

https://www.mdpi.com/1718-7729/32/8/460

Similar Items